Recent Major Changes
Warnings and Precautions, Pseudoaldosteronism (5.4) 10/2024
The following Structured Product Label (SPL) was submitted to the FDA by Golden State Medical Supply, Inc. for the product Posaconazole (NDC 51407-676). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding recent major changes, 1.2 prophylaxis of invasive aspergillusand candidainfections, 2.1 important administration instructions, 2.2 recommended dosage of posaconazole delayed-release tablets in adult patients, 2.3 recommended dosage of posaconazole delayed-release tablets for the prophylaxis of invasive aspergillusand candidainfections in pediatric patients (ages 13 to less than 18 years of age), 2.7 administration instructions for posaconazole delayed-release tablets, 2.9 non-substitutability between noxafil ®oral suspension and other formulations, 2.11 dosage modifications in patients with renal impairment, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Warnings and Precautions, Pseudoaldosteronism (5.4) 10/2024
Posaconazole delayed-release tablets are indicated for the prophylaxis of invasive Aspergillusand Candidainfections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows:
Additional Pediatric Use information is approved for Merck Sharp & Dohme Corp.’s NOXAFIL(posaconazole) delayed-release tablets. However, due to Merck Sharp & Dohme Corp.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Non-substitutable
Posaconazole delayed-release tablets are not substitutable with Noxafil
®Oral Suspension or Noxafil
®PowderMix for Delayed-Release Oral Suspension due to the differences in the dosing of each formulation. Therefore, follow the specific dosage recommendations for each of the formulations
[see
Dosage and Administration (2.2,
2.3)]
.
Posaconazole delayed-release tablets
The recommended dosage of posaconazole delayed-release tablets in adult patients for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised is shown in Table 1 [see Dosage and Administration (2.7, 2,9) and Clinical Pharmacology ( 12.3)].
Dosage | Duration of Therapy |
| Prophylaxis of Invasive Aspergillusand CandidaInfections | |
Posaconazole Delayed-Release Tablets: Loading dose: 300 mg (three 100 mg delayed-release tablets) twice a day on the first day. Maintenance dose: 300 mg (three 100 mg delayed-release tablets) once a day, starting on the second day. | Loading dose: 1 day Maintenance dose:Duration of therapy is based on recovery from neutropenia or immunosuppression |
Posaconazole delayed-release tablets
The recommended dosage of posaconazole delayed-release tablets in pediatric patients 13 years of age and older who weigh greater than 40 kg for the prophylaxis of invasive Aspergillusand Candidainfections is shown in Table 2 [see Dosage and Administration (2.7, 2.9) and Clinical Pharmacology (12.3)] .
Posaconazole delayed-release tablets are not recommended for use in pediatric patients who weigh 40 kg or less because the recommended dosage cannot be achieved with this dosage form.
Recommended Pediatric Dosage by Formulation | Duration of Therapy |
Posaconazole Delayed-Release Tablets (patients weighing greater than 40 kg): Loading dose: 300 mg (three 100 mg delayed-release tablets) twice a day on the first day.
Maintenance dose: 300 mg (three 100 mg delayed-release tablets) once a day, starting on the second day. | Prophylaxis of invasive Aspergillusand Candidainfections: Duration of therapy is based on recovery from neutropenia or immunosuppression. |
Additional Pediatric Use information is approved for Merck Sharp & Dohme Corp.’s NOXAFIL(posaconazole) delayed-release tablets. However, due to Merck Sharp & Dohme Corp.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Posaconazole delayed-release tablets are not substitutable with Noxafil ®Oral Suspension or Noxafil ®PowderMix for Delayed-Release Oral Suspension due to the differences in the dosing of each formulation. Therefore, follow the specific dosage recommendations for each of the formulations [see Dosage and Administration (2.2, 2.3)] .
The recommended dosage of posaconazole delayed-release tablets is the same in patients with renal impairment compared to those with normal renal function.
Posaconazole delayed-release tablets are available as yellow, modified, oval, convex tablets debossed with a logo "M" inside a square on one side and "100" on the opposite side containing 100 mg of posaconazole.
Posaconazole delayed-release tablets are contraindicated in persons with known hypersensitivity to posaconazole or other azole antifungal agents.
Posaconazole delayed-release tablets are contraindicated with sirolimus. Concomitant administration of posaconazole delayed-release tablets with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)] .
Posaconazole delayed-release tablets are contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant administration of posaconazole delayed-release tablets with the CYP3A4 substrates, pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and cases of torsades de pointes [see Warnings and Precautions (5.2)and Drug Interactions (7.2)] .
Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, and simvastatin) is contraindicated since increased plasma concentration of these drugs can lead to rhabdomyolysis [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)] .
Posaconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) which may lead to ergotism [see Drug Interactions (7.2)] .
Coadministration of posaconazole delayed-release tablets with venetoclax at initiation and during the ramp-up phase is contraindicated in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) due to the potential for increased risk of tumor lysis syndrome [see Warnings and Precautions (5.11) and Drug Interactions (7.2)] .
Concomitant administration of posaconazole delayed-release tablets with cyclosporine or tacrolimus increases the whole blood trough concentrations of these calcineurin-inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)] . Nephrotoxicity and leukoencephalopathy (including deaths) have been reported in clinical efficacy studies in patients with elevated cyclosporine or tacrolimus concentrations. Frequent monitoring of tacrolimus or cyclosporine whole blood trough concentrations should be performed during and at discontinuation of posaconazole treatment and the tacrolimus or cyclosporine dose adjusted accordingly.
Some azoles, including posaconazole, have been associated with prolongation of the QT interval on the electrocardiogram. In addition, cases of torsades de pointes have been reported in patients taking posaconazole.
Results from a multiple time-matched ECG analysis in healthy volunteers did not show any increase in the mean of the QTc interval. Multiple, time-matched ECGs collected over a 12-hour period were recorded at baseline and steady-state from 173 healthy male and female volunteers (18-85 years of age) administered Noxafil ®Oral Suspension 400 mg twice daily with a high-fat meal. In this pooled analysis, the mean QTc (Fridericia) interval change from baseline was –5 msec following administration of the recommended clinical dose. A decrease in the QTc(F) interval (–3 msec) was also observed in a small number of subjects (n=16) administered placebo. The placebo-adjusted mean maximum QTc(F) interval change from baseline was <0 msec (–8 msec). No healthy subject administered posaconazole had a QTc(F) interval ≥500 msec or an increase ≥60 msec in their QTc(F) interval from baseline.
Posaconazole should be administered with caution to patients with potentially proarrhythmic conditions. Do not administer with drugs that are known to prolong the QTc interval and are metabolized through CYP3A4 [see Contraindications (4.3)and Drug Interactions (7.2)] .
Electrolyte disturbances, especially those involving potassium, magnesium or calcium levels, should be monitored and corrected as necessary before and during posaconazole therapy.
Pseudoaldosteronism, manifested by the onset of hypertension or worsening of hypertension, and abnormal laboratory findings (hypokalemia, low serum renin and aldosterone, and elevated 11-deoxycortisol), has been reported with posaconazole use in the postmarket setting. Monitor blood pressure and potassium levels and manage as necessary. Management of pseudoaldosteronism may include discontinuation of posaconazole delayed-release tablets, substitution with an appropriate antifungal drug that is not associated with pseudoaldosteronism, or use of aldosterone receptor antagonists.
Hepatic reactions (e.g., mild to moderate elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total bilirubin, and/or clinical hepatitis) have been reported in clinical trials. The elevations in liver tests were generally reversible on discontinuation of therapy, and in some instances these tests normalized without drug interruption. Cases of more severe hepatic reactions including cholestasis or hepatic failure including deaths have been reported in patients with serious underlying medical conditions (e.g., hematologic malignancy) during treatment with posaconazole. These severe hepatic reactions were seen primarily in subjects receiving the Noxafil ®Oral Suspension 800 mg daily (400 mg twice daily or 200 mg four times a day) in clinical trials.
Liver tests should be evaluated at the start of and during the course of posaconazole therapy. Patients who develop abnormal liver tests during posaconazole therapy should be monitored for the development of more severe hepatic injury. Patient management should include laboratory evaluation of hepatic function (particularly liver tests and bilirubin). Discontinuation of posaconazole must be considered if clinical signs and symptoms consistent with liver disease develop that may be attributable to posaconazole.
Due to the variability in exposure with posaconazole delayed-release tablets, Noxafil ®Oral Suspension, and Noxafil ®PowderMix for Delayed-Release Oral Suspension, patients with severe renal impairment should be monitored closely for breakthrough fungal infections [see Dosage and Administration (2.11) and Use in Specific Populations (8.6)] .
Concomitant administration of posaconazole delayed-release tablets with midazolam increases the midazolam plasma concentrations by approximately 5-fold. Increased plasma midazolam concentrations could potentiate and prolong hypnotic and sedative effects. Patients must be monitored closely for adverse effects associated with high plasma concentrations of midazolam and benzodiazepine receptor antagonists must be available to reverse these effects [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)] .
Concomitant administration of azole antifungals, including posaconazole delayed-release tablets, with vincristine has been associated with neurotoxicity and other serious adverse reactions, including seizures, peripheral neuropathy, syndrome of inappropriate antidiuretic hormone secretion, and paralytic ileus. Reserve azole antifungals, including posaconazole delayed-release tablets, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options [see Drug Interactions (7.2)] .
Patients who have severe diarrhea or vomiting should be monitored closely for breakthrough fungal infections when receiving posaconazole delayed-release tablets.
Concomitant administration of posaconazole delayed-release tablets, a strong CYP3A4 inhibitor, with venetoclax may increase venetoclax toxicities, including the risk of tumor lysis syndrome (TLS), neutropenia, and serious infections. In patients with CLL/SLL, administration of posaconazole delayed-release tablets during initiation and the ramp-up phase of venetoclax is contraindicated [see Contraindications (4.6)] . Refer to the venetoclax labeling for safety monitoring and dose reduction in the steady daily dosing phase in CLL/SLL patients.
For patients with acute myeloid leukemia (AML), dose reduction and safety monitoring are recommended across all dosing phases when coadministering posaconazole delayed-release tablets with venetoclax [see Drug Interactions (7.2)] . Refer to the venetoclax prescribing information for dosing instructions.
The following serious and otherwise important adverse reactions are discussed in detail in another section of the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of posaconazole delayed-release tablets cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Clinical Trial Experience with Posaconazole Delayed-Release Tablets for Prophylaxis of Invasive Aspergillusand CandidaInfections
The safety of posaconazole delayed-release tablets has been assessed in 230 patients in clinical trials. Patients were enrolled in a non-comparative pharmacokinetic and safety trial of posaconazole delayed-release tablets when given as antifungal prophylaxis (Posaconazole Delayed-Release Tablet Study). Patients were immunocompromised with underlying conditions including hematological malignancy, neutropenia postchemotherapy, GVHD, and post HSCT. This patient population was 62% male, had a mean age of 51 years (range 19-78 years, 17% of patients were ≥65 years of age), and were 93% White and 16% Hispanic. Posaconazole delayed-release tablets were given for a median duration of 28 days. In this study, 20 adult patients received 200 mg daily dosage (this is not a recommended dosage [see Dosage and Administration (2.2)]) and 210 adult patients received 300 mg daily dosage (following twice daily dosing on Day 1 in each cohort). Table 9 presents adverse reactions (incidence of ≥10%) observed in patients treated with the posaconazole delayed-release tablets 300 mg daily dosage in the Posaconazole Delayed-Release Tablets Study.
The most frequently reported adverse reactions (>25%) in patients treated with posaconazole delayed-release tablets 300 mg once daily were diarrhea, pyrexia, and nausea. The most common adverse reaction leading to discontinuation of posaconazole delayed-release tablets 300 mg once daily was nausea (2%).
Table 9: Adverse Reactions in at least 10% of Adults Receiving Posaconazole Delayed-Release Tablets (300 mg Daily Dosage) for the Prophylaxis of Invasive Aspergillusand Candidainfections
| Adverse Reactions | Posaconazole delayed-release tablet (300 mg) n=210 (%) |
| Percentage of Patients Reporting any Adverse Reaction | 99 |
| Diarrhea | 29 |
| Pyrexia | 28 |
| Nausea | 27 |
| Hypokalemia | 22 |
| Cough | 17 |
| Edema Peripheral | 16 |
| Rash | 16 |
| Epistaxis | 14 |
| Headache | 14 |
| Mucosal Inflammation | 14 |
| Thrombocytopenia | 14 |
| Vomiting | 13 |
| Abdominal Pain | 11 |
| Hypertension | 11 |
| Anemia | 10 |
| Asthenia | 10 |
| Chills | 10 |
| Constipation | 10 |
| Hypomagnesemia | 10 |
Additional Pediatric Use information is approved for Merck Sharp & Dohme Corp.’s NOXAFIL (posaconazole) delayed-release tablets. However, due to Merck Sharp & Dohme Corp.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
The following adverse reaction has been identified during the post-approval use of posaconazole. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Endocrine Disorders: Pseudoaldosteronism
Table 15 and Table 17 include drugs with clinically important drug interactions when administered concomitantly with posaconazole delayed-release tablets and instructions for preventing or managing them.
These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy [see Clinical Pharmacology (12.3)] .
The following information was derived from data with Noxafil ®oral suspension or another posaconazole tablet formulation unless otherwise noted. All clinically important drug interactions with Noxafil ®oral suspension, except for those that affect the absorption of posaconazole (via gastric pH and motility), are considered relevant to clinically important drug interactions with posaconazole delayed-release tablets [ Clinical Pharmacology (12.3)] .
Consult the labeling of concomitantly used drugs to obtain further information about interactions with posaconazole.
Posaconazole is primarily metabolized via UDP-glucuronosyltransferase and is a substrate of p--glycoprotein (P-gp) efflux. Therefore, inhibitors or inducers of these clearance pathways may affect posaconazole plasma concentrations. Concomitant use of posaconazole delayed-release tablets with drugs that can decrease the plasma posaconazole concentrations should generally be avoided unless the benefit outweighs the risk. If such drugs are necessary, patients should be monitored closely for breakthrough fungal infections.
Table 15: Drug Interactions Affecting Posaconazole Delayed-Release Tablets When Administered Concomitantly with Other Drugs
UDP-Glucuronidase Inducers | ||
Mechanism and Clinical Effect(s) | Posaconazole is a UDP-glucuronosyltransferase substrate. Concomitant use of posaconazole delayed-release tablets with UDP-glucuronidase inducers may decrease posaconazole exposure [see Clinical Pharmacology (12.3)], which may reduce the effectiveness of posaconazole. | |
Prevention or Management | Efavirenz | Avoid concomitant use of posaconazole with efavirenz, unless the benefit outweighs the risks. |
Rifabutin | Avoid concomitant use of posaconazole with rifabutin unless the benefit to the patient outweighs the risk. If concomitant use is needed, monitor closely for breakthrough fungal infections. See Table 17 for rifabutin monitoring considerations when posaconazole affects rifabutin via CYP3A4 inhibition. | |
Phenytoin | Avoid concomitant use of posaconazole with phenytoin unless the benefit to the patient outweighs the risk. If concomitant use is needed, monitor for breakthrough fungal infections. See Table 17 for phenytoin monitoring considerations when posaconazole affects phenytoin via CYP3A4 inhibition. | |
Fosamprenavir | ||
Mechanism and Clinical Effect(s) | Concomitant use of posaconazole delayed-release tablets with fosamprenavir may lead to decreased posaconazole plasma concentrations [see Clinical Pharmacology (12.3)], which may reduce effectiveness of posaconazole. | |
Prevention or Management | If concomitant use of posaconazole with fosamprenavir is needed, monitor closely for breakthrough fungal infections. | |
Posaconazole is a strong CYP3A4 inhibitor. Therefore, concomitant use of posaconazole delayed-release tablets may increase plasma concentrations of drugs that are CYP3A4 substrates [see Clinical Pharmacology (12.3)].
Table 17: Drug Interactions Affecting Drugs Administered Concomitantly with Posaconazole Delayed-Release Tablets
Digoxin | ||
Clinical Effect(s) | Increased digoxin plasma concentrations have been reported in patients who received concomitant posaconazole and digoxin. | |
Prevention or Management | Monitor digoxin plasma concentrations during concomitant use of posaconazole. | |
Glipizide | ||
Clinical Effect(s) | No dosage modification of glipizide is needed when used concomitantly with posaconazole delayed-release tablets. However, glucose concentrations decrease in some patients concomitantly administered posaconazole and glipizide. | |
Prevention or Management | Increase monitoring of glucose concentrations when used concomitantly. | |
CYP3A Substrates | ||
Immunosuppressants that are CYP3A4 Substrates | ||
Mechanism and Clinical Effect(s) | Posaconazole is a strong CYP3A4 inhibitor. Therefore, plasma concentrations of CYP3A4 substrates may be increased by posaconazole use [see Clinical Pharmacology (12.3)]. | |
Prevention or Management | Sirolimus | Posaconazole is contraindicated with sirolimus [see Clinical Pharmacology (12.3)] . |
Tacrolimus |
| |
Cyclosporine |
| |
CYP3A4 Substrates that Prolong QTc Interval | ||
Mechanism and Clinical Effect(s) | Concomitant use of posaconazole with CYP3A4 substrates such as pimozide and quinidine may result in increased plasma concentrations of the CYP3A4 substrates leading to QTc interval prolongation and torsades de pointes [see Warnings and Precautions (5.2)]. | |
Prevention or Management | Pimozide | Concomitant use with posaconazole is contraindicated. |
Quinidine | ||
HMG-CoA Reductase Inhibitors (Statins) that are CYP3A4 Substrates | ||
Mechanism and Clinical Effect(s) | Concomitant use of posaconazole with simvastatin increased simvastatin plasma concentrations which can lead to rhabdomyolysis [see Clinical Pharmacology (12.3)]. | |
Prevention or Management | Atorvastatin, Lovastatin, Simvastatin | Concomitant use with posaconazole is contraindicated. |
Benzodiazepines that are CYP3A4 Substrates | ||
Mechanism and Clinical Effect(s) | Concomitant use of posaconazole with midazolam increased midazolam plasma concentrations which could potentiate and prolong hypnotic and sedative effects [see Clinical Pharmacology (12.3)] . | |
Prevention or Management | Midazolam, Alprazolam, Triazolam | Closely monitor for adverse reactions associated with high plasma concentrations of benzodiazepines that are CYP3A4 substrates during concomitant use, and a benzodiazepine receptor antagonist should be available to reverse effects [see Warnings and Precautions (5.7)]. |
Calcium Channel Blockers that are CYP3A4 Substrates | ||
Mechanism and Clinical Effect(s) | Posaconazole may increase the plasma concentrations of calcium channel blockers that are substrates of CYP3A4. | |
Prevention or Management | Verapamil, Diltiazem, Nifedipine, Nicardipine, Felodipine | Monitor frequently for adverse reactions and toxicity with concomitant use of posaconazole with calcium channel blockers that are CYP3A4 substrates. Dosage reduction of the calcium channel blocker may be needed. |
Anti-HIV Drugs that are CYP3A4 Substrates | ||
Mechanism and Clinical Effect(s) | Ritonavir and atazanavir are CYP3A4 substrates and posaconazole increased plasma concentrations of these drugs [see Clinical Pharmacology (12.3)]. | |
Prevention or Management | Ritonavir and Atazanavir | Monitor frequently for adverse reactions and toxicity of ritonavir and atazanavir during concomitant use. |
Antineoplastic Drugs that are CYP3A4 Substrates | ||
Mechanism and Clinical Effect(s) | Posaconazole may increase plasma concentrations of oncology drugs that are CYP3A4 substrates, which may increase the risk of serious adverse reactions. | |
Prevention or Management | Venetoclax | CLL/SLL patients :Concomitant use of posaconazole with venetoclax during initiation and ramp-up phase is contraindicated. AML patients :With concomitant use, venetoclax dosage reduction and safety monitoring is recommended across all dosing phases [see Warnings and Precautions (5.11)] . |
Vinca alkaloids (e.g., vincristine, vinblastine) | Reserve concomitant use for patients with no alternative antifungal treatment options [see Warnings and Precautions (5.8)]. | |
Ergot Alkaloids | ||
Mechanism and Clinical Effect(s) | Most of the ergot alkaloids are CYP3A4 substrates. Posaconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) which may lead to ergotism. | |
Prevention or Management | Ergotamine, Dihydroergot amine | Concomitant use with posaconazole is contraindicated. |
Phenytoin | ||
Mechanism and Clinical Effect(s) | Phenytoin is a CYP3A4 substrate. Concomitant use of posaconazole with phenytoin increased phenytoin plasma concentrations [see Clinical Pharmacology (12.3)]. | |
Prevention or Management | Avoid concomitant use of posaconazole with phenytoin unless the benefit outweighs the risk. frequently monitor phenytoin concentrations and consider a dosage reduction of phenytoin. See Table 15 for additional monitoring considerations when phenytoin affects posaconazole via UDP-glucuronosyltransferase inhibition. | |
Rifabutin | ||
Mechanism and Clinical Effect(s) | Rifabutin is a CYP3A4 substrate. Concomitant use of posaconazole with rifabutin increased rifabutin plasma concentrations [see Clinical Pharmacology (12.3)]. | |
Prevention or Management | Avoid concomitant use of posaconazole with rifabutin unless the benefit outweighs the risk. Frequent monitoring of full blood counts and adverse reactions due to increased rifabutin plasma concentrations (e.g., uveitis, leukopenia) during concomitant use are recommended. See Table 15 for additional monitoring considerations when rifabutin affects posaconazole via UDP-glucuronosyltransferase inhibition. | |
Additional clinical studies demonstrated that no clinically important effects on zidovudine, lamivudine, indinavir, or caffeine were observed when administered with Noxafil 200 mg once daily; therefore, no dose adjustments are required for these drugs when coadministered with Noxafil 200 mg once daily.
No clinically relevant effects on the pharmacokinetics of posaconazole delayed-release tablets were observed during concomitant use with antacids, H 2-receptor antagonists and proton pump inhibitors, and metoclopramide [see Clinical Pharmacology (12.3)] . No dosage adjustment of posaconazole delayed-release tablets is required during concomitant use with these drugs. No clinically relevant effects on the pharmacokinetics of Noxafil ®oral suspension were observed during concomitant use with antacids, H 2-receptor antagonists (other than cimetidine), and loperamide [see Clinical Pharmacology (12.3)] . No dosage adjustment of Noxafil ®oral suspension is required during concomitant use with these drugs (other than cimetidine).
Risk Summary
Based on findings from animal data, posaconazole delayed-release tablets may cause fetal harm when administered to pregnant women. Available data for use of posaconazole delayed-release in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, skeletal malformations were observed when posaconazole was dosed orally to pregnant rats during organogenesis at doses ≥1.4 times the 400 mg twice daily oral suspension regimen based on steady-state plasma concentrations of posaconazole delayed-release in healthy volunteers. In pregnant rabbits dosed orally during organogenesis, doses of ≥ 3 times the clinical exposure caused an increase in resorptions (see Data). Based on animal data, advise pregnant women of the potential risk to a fetus.
The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Risk Summary
There are no data on the presence of posaconazole in human milk, the effects on the breastfed infant, or the effects on milk production. Posaconazole is excreted in the milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for posaconazole delayed-release tablets and any potential adverse effects on the breastfed child from posaconazole delayed-release tablets or from the underlying maternal condition.
The safety and effectiveness of posaconazole delayed-release tablets have been established for the prophylaxis of invasive Aspergillusand Candidainfections in pediatric patients 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised.
Use of posaconazole delayed-release tablets for these pediatric indications is supported by adequate and well controlled studies of posaconazole delayed-release tablets in adults and pediatric patients aged 13 years of age and older [see Clinical Pharmacology (12.3) and Clinical Studies (14)].
The safety and effectiveness of posaconazole have not been established in pediatric patients younger than 2 years of age.
Additional Pediatric Use information is approved for Merck Sharp & Dohme Corp.’s NOXAFIL (posaconazole delayed-release tablets). However, due to Merck Sharp & Dohme Corp.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
No overall differences in the safety or effectiveness of posaconazole delayed-release tablets have been observed between geriatric patients and younger adult patients in the clinical trials; therefore, the recommended dosage in geriatric patients is the same as that for younger adult patients. No clinically meaningful differences in posaconazole pharmacokinetics were observed in posaconazole delayed-release tablets-treated geriatric patients compared to posaconazole delayed-release tablets -treated younger adult patients during clinical trials [see Clinical Pharmacology (12.3)] .
Posaconazole Delayed-Release Tablets
No dosage adjustment is required for patients with eGFR 20 mL/minute/1.73 m 2or higher. Due to variability in posaconazole exposure, closely monitor patients with eGFR less than 20 mL/minute/1.73 m 2for breakthrough fungal infections. [see Clinical Pharmacology (12.3)] .
No dosage adjustment is recommended for posaconazole delayed-release tablets in patients with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C, respectively) [see Clinical Pharmacology (12.3)] .
However, a specific hepatic impairment study has not been conducted with the posaconazole delayed-release tablets.
No adjustment in the dosage of posaconazole delayed-release tablets is necessary based on sex.
No adjustment in the dosage of posaconazole delayed-release tablets is necessary based on race.
Pharmacokinetic modeling suggests that patients who weigh greater than 120 kg may have lower posaconazole plasma drug exposure. Therefore, consider closely monitoring for breakthrough fungal infections particularly when using posaconazole delayed-release tablets in patients weighing greater than 120 kg [see Clinical Pharmacology (12.3)] .
There is no experience with overdosage of posaconazole delayed-release tablets.
During the clinical trials, some patients received Noxafil ®Oral Suspension up to 1,600 mg/day with no adverse reactions noted that were different from the lower doses. In addition, accidental overdose was noted in one patient who took 1200 mg twice daily Noxafil ®Oral Suspension for 3 days. No related adverse reactions were noted by the investigator.
Posaconazole is not removed by hemodialysis.
Posaconazole delayed-release tablets contain posaconazole, an azole antifungal agent.
Posaconazole is designated chemically as 4-[4-[4-[4-[[ (3 R,5 R)-5- (2,4-difluorophenyl)tetrahydro-5- (1 H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-[(1 S,2 S)-1-ethyl-2-hydroxypropyl]-2,4-dihydro-3 H-1,2,4-triazol-3-one with an empirical formula of C 37H 42F 2N 8O 4and a molecular weight of 700.8. The chemical structure is:
Posaconazole is a white powder with a low aqueous solubility.
Posaconazole delayed-release tablets are yellow, modified, oval, convex tablets containing 100 mg of posaconazole. Each delayed-release tablet contains the inactive ingredients: Hypromellose Acetate Succinate, Microcrystalline Cellulose, Hydroxypropyl Cellulose, Croscarmellose Sodium, Silicon Dioxide, and Magnesium Stearate. The color coating contains (Polyvinyl Alcohol, Titanium Dioxide, Polyethylene Glycol, Talc, Ferric Oxide Yellow, and Ferrosoferric Oxide).
Posaconazole is an azole antifungal agent [see Clinical Pharmacology (12.4)] .
Exposure Response Relationship: Prophylaxis of invasive Aspergillusand CandidaInfections in Adults Who Are at High Risk of Developing These Infections Due to Being Severely Immunocompromised
In clinical studies of neutropenic patients who were receiving cytotoxic chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) or hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), a wide range of plasma exposures to posaconazole was noted following administration of Noxafil ®Oral Suspension. A pharmacokinetic-pharmacodynamic analysis of patient data revealed an apparent association between average posaconazole concentrations (C avg) and prophylactic efficacy (Table 18). A lower C avgmay be associated with an increased risk of treatment failure, defined as treatment discontinuation, use of empiric systemic antifungal therapy (SAF), or occurrence of breakthrough invasive fungal infections.
| Prophylaxis in AML/MDS
Neutropenic patients who were receiving cytotoxic chemotherapy for AML or MDS | Prophylaxis in GVHD
HSCT recipients with GVHD | |||
| C avgRange (ng/mL) | Treatment Failure
Defined as treatment discontinuation, use of empiric systemic antifungal therapy (SAF), or occurrence of breakthrough invasive fungal infections (%) | C avgRange (ng/mL) | Treatment Failure
| |
Quartile 1 | 90-322 | 54.7 | 22-557 | 44.4 |
Quartile 2 | 322-490 | 37.0 | 557-915 | 20.6 |
Quartile 3 | 490-734 | 46.8 | 915-1563 | 17.5 |
Quartile 4 | 734-2200 | 27.8 | 1563-3650 | 17.5 |
| C avg= the average posaconazole concentration when measured at steady state | ||||
Carcinogenesis
No drug-related neoplasms were recorded in rats or mice treated with posaconazole for 2 years at doses higher than the clinical dose. In a 2 year carcinogenicity study, rats were given posaconazole orally at doses up to 20 mg/kg (females), or 30 mg/kg (males). These doses are equivalent to 3.9- or 3.5 times the exposure achieved with a 400 mg twice daily Noxafil
®Oral Suspension regimen, respectively, based on steady-state AUC in healthy volunteers administered a high-fat meal (400 mg twice daily Noxafil
®Oral Suspension regimen). In the mouse study, mice were treated at oral doses up to 60 mg/kg/day or 4.8 times the exposure achieved with a 400 mg twice daily Noxafil
®Oral Suspension regimen.
Mutagenesis
Posaconazole was not genotoxic or clastogenic when evaluated in bacterial mutagenicity (Ames), a chromosome aberration study in human peripheral blood lymphocytes, a Chinese hamster ovary cell mutagenicity study, and a mouse bone marrow micronucleus study.
Impairment of Fertility
Posaconazole had no effect on fertility of male rats at a dose up to 180 mg/kg (1.7 × the 400 mg twice daily Noxafil
®Oral Suspension regimen based on steady-state plasma concentrations in healthy volunteers) or female rats at a dose up to 45 mg/kg (2.2 × the 400 mg twice daily Noxafil
®Oral Suspension regimen).
Two randomized, controlled studies were conducted using posaconazole as prophylaxis for the prevention of invasive fungal infections (IFIs) among patients at high risk due to severely compromised immune systems.
The first study (Noxafil ®Oral Suspension Study 1) was a randomized, double-blind trial that compared Noxafil ®Oral Suspension (200 mg three times a day) with fluconazole capsules (400 mg once daily) as prophylaxis against invasive fungal infections in allogeneic hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD). Efficacy of prophylaxis was evaluated using a composite endpoint of proven/probable IFIs, death, or treatment with systemic antifungal therapy (patients may have met more than one of these criteria). This assessed all patients while on study therapy plus 7 days and at 16 weeks post-randomization. The mean duration of therapy was comparable between the 2 treatment groups (80 days, posaconazole; 77 days, fluconazole). Table 34 contains the results from Noxafil ®Oral Suspension Study 1.
| Posaconazole n=301 | Fluconazole n=299 | |
| On therapy plus 7 days | ||
|
Clinical Failure
Patients may have met more than one criterion defining failure. | 50 (17%) | 55 (18%) |
| Failure due to: | ||
| Proven/Probable IFI | 7 (2%) | 22 (7%) |
| ( Aspergillus) | 3 (1%) | 17 (6%) |
| ( Candida) | 1 (<1%) | 3 (1%) |
| (Other) | 3 (1%) | 2 (1%) |
| All Deaths | 22 (7%) | 24 (8%) |
| Proven/probable fungal infection prior to death | 2 (<1%) | 6 (2%) |
| SAF
Use of systemic antifungal therapy (SAF) criterion is based on protocol definitions (empiric/IFI usage >4 consecutive days). | 27 (9%) | 25 (8%) |
| Through 16 weeks | ||
| Clinical Failure
95% confidence interval (posaconazole-fluconazole) = (-11.5%, +3.7%). | 99 (33%) | 110 (37%) |
| Failure due to: | ||
| Proven/Probable IFI | 16 (5%) | 27 (9%) |
| ( Aspergillus) | 7 (2%) | 21 (7%) |
| ( Candida) | 4 (1%) | 4 (1%) |
| (Other) | 5 (2%) | 2 (1%) |
| All Deaths | 58 (19%) | 59 (20%) |
| Proven/probable fungal infection prior to death | 10 (3%) | 16 (5%) |
| SAF
| 26 (9%) | 30 (10%) |
| Event free lost to follow-up
Patients who are lost to follow-up (not observed for 112 days), and who did not meet another clinical failure endpoint. These patients were considered failures. | 24 (8%) | 30 (10%) |
The second study (Noxafil ®Oral Suspension Study 2) was a randomized, open-label study that compared Noxafil ®Oral Suspension (200 mg 3 times a day) with fluconazole suspension (400 mg once daily) or itraconazole oral solution (200 mg twice a day) as prophylaxis against IFIs in neutropenic patients who were receiving cytotoxic chemotherapy for AML or MDS. As in Noxafil ®Oral Suspension Study 1, efficacy of prophylaxis was evaluated using a composite endpoint of proven/probable IFIs, death, or treatment with systemic antifungal therapy (patients might have met more than one of these criteria). This study assessed patients while on treatment plus 7 days and 100 days post-randomization. The mean duration of therapy was comparable between the 2 treatment groups (29 days, posaconazole; 25 days, fluconazole or itraconazole). Table 35 contains the results from Noxafil ®Oral Suspension Study 2.
| Posaconazole n=304 | Fluconazole/Itraconazole n=298 | |
| On therapy plus 7 days | ||
| Clinical Failure
95% confidence interval (posaconazole-fluconazole/itraconazole) = (-22.9%, -7.8%). ,Patients may have met more than one criterion defining failure. | 82 (27%) | 126 (42%) |
| Failure due to: | ||
| Proven/Probable IFI | 7 (2%) | 25 (8%) |
| ( Aspergillus) | 2 (1%) | 20 (7%) |
| ( Candida) | 3 (1%) | 2 (1%) |
| (Other) | 2 (1%) | 3 (1%) |
| All Deaths | 17 (6%) | 25 (8%) |
| Proven/probable fungal infection prior to death | 1 (<1%) | 2 (1%) |
| SAF
Use of systemic antifungal therapy (SAF) criterion is based on protocol definitions (empiric/IFI usage >3 consecutive days). | 67 (22%) | 98 (33%) |
| Through 100 days post-randomization | ||
| Clinical Failure
| 158 (52%) | 191 (64%) |
| Failure due to: | ||
| Proven/Probable IFI | 14 (5%) | 33 (11%) |
| ( Aspergillus) | 2 (1%) | 26 (9%) |
| ( Candida) | 10 (3%) | 4 (1%) |
| (Other) | 2 (1%) | 3 (1%) |
| All Deaths | 44 (14%) | 64 (21%) |
| Proven/probable fungal infection prior to death | 2 (1%) | 16 (5%) |
| SAF
| 98 (32%) | 125 (42%) |
| Event free lost to follow-up
Patients who are lost to follow-up (not observed for 100 days), and who did not meet another clinical failure endpoint. These patients were considered failures. | 34 (11%) | 24 (8%) |
In summary, 2 clinical studies of prophylaxis were conducted with the Noxafil ®Oral Suspension. As seen in the accompanying tables ( Table 34 and Table 35), clinical failure represented a composite endpoint of breakthrough IFI, mortality and use of systemic antifungal therapy. In Noxafil ®Oral Suspension Study 1 ( Table 34), the clinical failure rate of posaconazole (33%) was similar to fluconazole (37%), (95% CI for the difference posaconazole–comparator -11.5% to 3.7%) while in Noxafil ®Oral Suspension Study 2 ( Table 35) clinical failure was lower for patients treated with posaconazole (27%) when compared to patients treated with fluconazole or itraconazole (42%), (95% CI for the difference posaconazole–comparator -22.9% to -7.8%).
All-cause mortality was similar at 16 weeks for both treatment arms in Noxafil ®Oral Suspension Study 1 [POS 58/301 (19%) vs. FLU 59/299 (20%)]; all-cause mortality was lower at 100 days for posaconazole-treated patients in Noxafil ®Oral Suspension Study 2 [POS 44/304 (14%) vs. FLU/ITZ 64/298 (21%)]. Both studies demonstrated fewer breakthrough infections caused by Aspergillusspecies in patients receiving posaconazole prophylaxis when compared to patients receiving fluconazole or itraconazole.
Posaconazole delayed-release tablets are available as yellow, modified, oval, convex tablets debossed with a logo "M" inside a square on one side and "100" on the opposite side containing 100 mg of posaconazole.
Bottles of 60 . . . . . . . . . . . . . . NDC 51407-676-60
Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Dispense in a tight, light-resistant container (as defined in USP) with a child-resistant closure.
Advise the patient to read the FDA-approved patient labeling ( Patient Information).
Important Administration Instructions
Posaconazole Delayed-Release Tablets
Advise patients that posaconazole delayed-release tablets must be swallowed whole and not divided, crushed, or chewed.
Instruct patients that if they miss a dose, they should take it as soon as they remember. If they do not remember until it is within 12 hours of the next dose, they should be instructed to skip the missed dose and go back to the regular schedule. Patients should not double their next dose or take more than the prescribed dose.
Drug Interactions
Advise patients to inform their physician immediately if they:
Serious and Potentially Serious Adverse Reactions
Advise patients to inform their physician immediately if they:
© 2026 Par Health, Inc. or one of its affiliates.
Noxafil, Mylanta, Zantac, Nexium, and Reglan are trademarks of their respective owners.
Manufactured for:
SpecGx LLC
Webster Groves, MO 63119 USA
www.parhealth.com or call 1-800-778-7898
L20P21
Revised: 02/2026
Par Health™
Marketed by:
GSMS, Inc.
Camarillo, CA 93012 USA
To obtain a printable copy of the Patient Information, visit www.parhealth.com/products |
| Patient Information Posaconazole (poe'' sa kon' a zole) delayed-release tablets |
| What are posaconazole delayed-release tablets? Posaconazole delayed-release tablets are a prescription medicine used in adults and children 13 years of age and older to help prevent fungal infections that can spread throughout your body (invasive fungal infections). These infections are caused by fungi called Aspergillusor Candida. Posaconazole delayed-release tablets are used in people who have an increased chance of getting these infections due to a weak immune system. These include people who have had a hematopoietic stem cell transplantation (bone marrow transplant) with graft-versus-host disease or those with a low white blood cell count due to chemotherapy for blood cancers (hematologic malignancies). Posaconazole delayed-release tabletsare used for:
It is not known if posaconazole delayed-release tablets are safe and effective in children under 2 years of age. |
Do not take posaconazole delayed-release tablets if you:
Ask your healthcare provider or pharmacist if you are not sure if you are taking any of these medicines. Do not start taking a new medicine without talking to your healthcare provider or pharmacist. |
Before you take posaconazole delayed-release tablets, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take,including prescription and over-the-counter medicines, vitamins, and herbal supplements. Posaconazole delayed-release tablets can affect the way other medicines work, and other medicines can affect the way posaconazole delayed-release tablets work, and can cause serious side effects. Especially tell your healthcare provider if you take: Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure. Know the medicines you take. Keep a list of them with you to show your healthcare provider or pharmacist when you get a new medicine. |
How should I take posaconazole delayed-release tablets?
Follow the instructions from your healthcare provider on how many posaconazole delayed-release tablets you should take and when to take them. |
| What are the possible side effects of posaconazole delayed-release tablets?
Posaconazole delayed-release tablets may cause serious side effects, including:
The most common side effects of posaconazole delayed-release tablets in adults include: If you take posaconazole delayed-release tablets, tell your healthcare provider right away if you have diarrhea or vomiting. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of posaconazole delayed-release tablets. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
How should I store posaconazole delayed-release tablets?
Keep posaconazole delayed-release tablets and all medicines out of the reach of children. |
| General information about the safe and effective use of posaconazole delayed-release tablets. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use posaconazole delayed-release tablets for a condition for which they were not prescribed. Do not give posaconazole delayed-release tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about posaconazole delayed-release tablets that is written for health professionals. |
What are the ingredients in posaconazole delayed-release tablets?
Additional Pediatric Use information is approved for Merck Sharp & Dohme Corp.’s NOXAFIL(posaconazole) delayed-release tablets. However, due to Merck Sharp & Dohme Corp.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. © 2026 Par Health, Inc. or one of its affiliates. Noxafil, Mylanta, Zantac, Nexium, and Reglan are trademarks of their respective owners. Manufactured for: SpecGx LLC Webster Groves, MO 63119 USA
Par Health™ Marketed by:
|
This Patient Information has been approved by the U.S. Food and Drug Administration.
Revised: 02/2026
X30000254
NDC 51407-676-60
60 TABLETS
Posaconazole
Delayed-Release Tablets
100 mg
Rx only
ATTENTION: Noxafil™ Oral Suspension and Posaconazole Delayed-Release Tablets are NOT interchangeable due to differences in the dosing of each formulation.
PHARMACIST: Dispense the Patient Information provided separately to each patient.
* Please review the disclaimer below.